Adjuvant Capital

Adjuvant is a new type of venture capital firm. We finance the most promising life science technologies for high-burden public health challenges. We see enormous opportunities in historically overlooked market segments, and we leverage our unique expertise to translate these opportunities into social and financial returns for our investors.

The Adjuvant Investment Strategy

Adjuvant’s strategy aims to drive meaningful improvements in the public health of low- and middle-income countries while pursuing top-tier financial returns. Adjuvant’s focus areas include:

• Neglected, high-burden, and emerging infectious diseases, including antimicrobial resistance and pandemic threats
• Maternal, newborn, and child health challenges
• Reproductive and sexual health
• Nutrition

Adjuvant directs the majority of its investment activity to opportunities that have human efficacy signals from a phase II-or-later clinical trial or similar arm’s-length evaluations. We look for compelling proof-of-concept data to support our investment decisions.